

CURRICULUM VITAE

Charles H G Davis
Honorary Clinical Professor Neurosurgery & Oncology
Consultant Neurosurgeon

Honorary Fellow University of Central Lancashire 2012.

Past President (2009 to 2011) British Neuro-Oncology Society.

Consultant Neurosurgeon, Regional Neuroscience Unit for Lancashire and South Cumbria, Royal Preston Hospital. (Lancashire Teaching Hospitals NHS Trust) 1987 to April 2016.

Vice President British Neuro-Oncology Society 2007 to 2009.

Honorary Clinical Professor Neurosurgery & Oncology (University of Central Lancashire).

Co-Director Lancashire Teaching/University of Central Lancashire Neuro-Oncology the largest Research Unit in the UK.

Director Spine Care UK Ltd. Visiting Consultant Carlisle, Penrith, Workington.

Honorary Consultant Neurosurgeon Wrightington Hospital, Wigan.

Consultant Neurosurgeon Ramsay Fulwood Hall Hospital, Spire Fylde Coast Hospital, BMI Lancaster

Founder Member and Director Brain Tumour North West (largest research consortium brain tumours in UK)

Chair North and Midlands Patient Support Advisory Committee Brain Tumour UK.

High Grade Glioma UK Study Group Member.

Chair British Neuro-Oncology Society Surgical Committee 2008 – 2012.

Visiting Fellow University of Central Lancashire 1998 to 2010.

Founder Member British Cervical Spine Society and British Neurosurgery Research Society.

Member of the Society of British Neurological Surgeons and British Association of Spinal Surgeons.

Clinical Lead North West Neuroscience Clinical Partnership 2000 to 2005.

2005 Society of British Neurological Surgeons Working Party NICE - Brain Tumours.

2008 Committee BNOS Rare Tumour Guidelines for NICE.

2008 Committee Map of Medicine Guidelines.

Clinical Director Neurosciences Lancashire and South Cumbria 1997 to 2005.

Lead CNS/Oncology 1987 to 2009, Lancashire Teaching Hospitals NHS Trust.

Member of Cancer Research Network Lancashire and South Cumbria 2006 to 2012.

MRC Brain Tumour Working Party 1985 – 1989.

Founder Member Expert Witness Institute.

Member of Academy of Experts.

EDUCATION

Westminster School, St Bartholomew's Hospital.

NEUROSURGICAL TRAINING

St Bartholomew's Hospital 1974.

Maudsley Hospital 1978-1981 (Guy's and King's College Hospitals).

National Hospital for Nervous Diseases, Hospital for Sick Children Great Ormond Street and Charing Cross Hospital 1981 -1986.

QUALIFICATIONS

M.R.C.S., L.R.C.P.	-	1971
M.B.B.S.	-	1972
F.R.C.S.	-	1978

MEDICO-LEGAL

30 years undertaking medico-legal reporting – Personal Injury and Clinical Negligence.

75 personal injury per year.

30 medical negligence per year.

80% Claimant.

20% Defendant.

Bond Solon Courses.

ICO No: 00010993086

Area of Expertise:

- Head and Brain Injury.
- Neurosurgery.
- Spinal Surgery.
- Whiplash.
- Pain.
- Nerve Injury.
- Spinal Cord Stimulation.
- Neuro-oncology.

Free CPR compliant telephone discussion.

Short appointment waiting time.

SPECIALIST CLINICAL ACHIEVEMENTS

Development of first UK Neuro-Oncology Service 1987.

First Meningioma Clinic UK 1988.

Introduction of first CRW CT Stereotactic Frame (first commercial frame) in Europe 1989.

Development of first UK joint Spinal (Neuro-Orthopaedic) Clinic 1988.

Introduction of MR Stereotaxy.

Founder and Moderator of North West Regional Neurosurgical Training Scheme 1994 – 2004.

First to measure intrasyrinx pressure.

First Neuro-Orthopaedic Service 1989.

BOOKS

1. **Disc and degenerative disease: Stenosis, spondylosis, subluxation.**
Davis C.
157-180 in Diseases of the Spinal Cord Critchley E., Eisen A. Springer Verlag 1992 (first edition):-
Second edition 1997.

2. **A surgical history of Maida Vale Hospital**
Davis C., Bradford R.
Chapter 33; 245-249. In Biology of Brain tumour. Walker M.D., and Thomas D.G.T. (Eds).
Martinus Nijhoff, Boston. 1986.

3. **Steroid sex hormones in non pituitary tumours.**
Davis C., Jones., Yoshino E., Darling J., Carter G., Zaher J., Thomas D.
Pages 165-167: In Brain Oncology. Chatel M., Darsel F., Pecker J., (Eds). Martinus Nijhoff,
Dordrecht. 1987.

4. **Factors influencing vasospasm in aneurysmal subarachnoid haemorrhage – A prospective observational study in the North of England.**
Chapter 46, page 194, in “Cerebral vasospasm-Advances in research and treatment”. Thieme publications, 2003; Editor: R. Loch Macdonald. Authors: Venkatachalam R., Hunt L., Likhith A., Gurusinge N., Roberts G., Davis C., Lye R.

5. **Diagnosis and treatment of malignant glioma.**
Iyer RV., Golash A., Lea RW., Davis CHG., Roberts P.
Chapter 14, Pages 379-408, n The Molecular and Cellular Pathology of Cancer Progression and Prognosis. Ed Sherbet GV. ISBN:8\-7736-283-6.

JOURNALS (including abstracts, the majority of which are subject to peer review).

1. **The late diagnosis by CT of unsuspected extradural haematoma.**
Davis C., Nichols R.
Lancet 1980; 1:416
2. **Cerebellar astrocytomas in children and young adults. Clinico-pathological review of 43 cases.**
Davis C., Joglekar V.
Journal of Neurology, Neurosurgery and Psychiatry 1981; 44: 820-828.
3. **Metastasis of carcinoma to meningioma and glioma.**
Joglekar V., Davis, Blakeney C.
Acta Neurochirurgica 1981; 58: 67-74.
4. **Operating microscopes and magnification systems.**
Davis C.
British Journal of Hospital Medicine 1981; 26: 291-296.
5. **Capillary haemangioblastoma of bone resembling cavernous haemangioma.**
Stephens J., Kendall B., Love., Davis C.
British Journal of Radiology 1983; 56: 571-575.
6. **The management of cerebral arteriovenous malformations.**
Davis C.
Lancet 1983; 1: 1391.
7. **Cerebral angiomas. Review and re-appraisal.**
Davis C., Symon I.
Acta Neurochirurgica. 1984; 70: 137.
8. **Spinal Blastomycosis: case report.**
Krarup C., Davis C., Symon I., Harding B.N.
Journal of Neurology, Neurosurgery and Psychiatry 1984; 47: 217-218.
9. **The management of cerebral angiomas. Review of 129 cases.**
Davis C., Symon I.
Acta Neurochirurgica 1985; 74: 4-12.
10. **Syringo-peritoneal shunt: Review of 29 cases.**
Suzuki M., Davis C., Gentili R., Symon L.
Journal of Neurology, Neurosurgery and Psychiatry 1985; 48: 620-627.
11. **Malignant behaviour of myxo-papillary ependymoma.**
Davis C., Barnard R.
Journal of Neurosurgery 1985; 62: 925.

12. **Spinal cord damage due to osteopathic manipulation.**
Davis C.
British Medical Journal 1985; 2: 1450.
13. **Stereotactic biopsy of brain under MR Imaging control.**
Thomas D.G.T., Davis C., Ingrams S., Olney J.S., Bydder G.M., and Young I.R.
American Journal of Neuroradiology 1986; 7: 161-163.
14. **Posterior fossa ependymoma in adults. Review of 16 cases.**
Davis C., Symon L.
Acta Neurochirurgica. 1986; 82: 115-117.
15. **Osteopathic manipulation resulting in damage to the spinal cord.**
Davis C.
British Medical Journal. 1986; 1:205.
16. **History of Maida Vale Hospital.**
Davis C., Bradford R.
Journal of Neuro-oncology. Special supplement. 1986.
17. **Percutaneous insertion of the spinal end of a cystoperitoneal shunt as a definitive treatment to relieve cord compression.**
Stevens J., Kendall B., Davis C., Crockard H.A.
Neuroradiology 1987; 29: 190-195
18. **Partial posterior vertebrectomy for anterior thoracic cord compression.**
Davis C.
British Journal of Neurosurgery, 1987; 1: 277-279.
19. **Clinical magnetic susceptibility mapping of the brain.**
Young I.R., Khenia S., Thomas D.G.T., Davis C., Gadian D.G., Cox I.J., Ross B.D., Bydder G.M.
Journal of Computer Assisted Tomography, 1987; 1:2-6.
20. **Clinical use of Rapid T2 weighted partial saturation sequences.**
Bydder G.M., Payne J.A., Collins A.G., Thomas D.G.T., Davis C., Cox I.J., Ross B.D., Young I.R.
Journal of Computer Assisted Tomography 1987; 1: 17-23.
21. **Computer directed stereotactic biopsy of intrinsic brainstem lesions.**
Thomas D., Bradford R., Gill S., Davis C.
British Journal of Neurosurgery. 1988; 2: 235-240.
22. **Mechanisms and treatment in post traumatic syringomyelia.**
Davis C., Symon L.
British Journal of Neurosurgery. 1989; 3: 669-674

- 23. Preston/Christie Stereotactic Frame – A further economic modification of the Leksell Frame.**
Jones A., Sofat A., Denten S., Davis C., Gurusinghe N.
British Journal of Neurosurgery. 1989.
- 24. Hyponatremia treatment by Urea and Saline.**
Davis C.
Journal of Neurosurgery. 1989; 71: 794.
- 25. Nimodipine and cerebral ischaemia following subarachnoid haemorrhage.**
Keogh A., Davis C.
Journal of Neurosurgery. 1990; 4: 355.
- 26. A low cost modification of an old Leksell stereotactic frame to allow CT guided stereotaxy.**
Jones A.P., Sofat A., Davis C., Denton S., Gurusinghe N.
British Journal of Neurosurgery. 1990; 4(3): 193-197.
- 27. Meningiomas and sex hormones.**
Davis C.
European Journal of Cancer. 1990; 8: 859-860.
- 28. Meningiomas and sex hormones, radiotherapy and benign brain tumours.**
Davis C.
European Journal of Cancer 27. 1991; 9: 1185.
- 29. CT Stereotactic Surgical Approaches using the CRW III Frame.**
Pandya P.M., Davis C.H.G.,
British Journal of Neurosurgery. 1991;5: 213
- 30. An empty mucocele of sphenoid sinus.**
Davis C., Small M., Lund V.
British Journal of Neurosurgery. 1992; 6: 381-384.
- 31. Transsphenoidal pituitary surgery**
Davis C.
British Journal of Neurosurgery. 1992; 6:506.
- 32. Primary dorsal exophytic ependymoma.**
Parekh H., Sharma R., Bertolis G., Davis C., Prabhu S.
British Journal of Neurosurgery. 1993; 7: 201-204.
- 33. The Impact of CT Stereotaxy on Tumour Surgery for the 1990s.**
Sharma R.R., Parekh H.C., Davis C.H.G.
British Journal of Neurosurgery. 1993;7: 105-106.
- 34. Pathogenesis of post-traumatic syringomyelia.**
Davis C.
British Journal of Neurosurgery. 1993; 7: 447-448.

35. **Treatment of Malignant Glioma with Short Course Radiotherapy and the PCV Regime.**
British Journal of Neurosurgery. 1994;8: 255-256.
36. **Minimally Invasive Neurosurgery using CRW-3 Stereotaxy.**
Sharma R.R., Davis C.H.G., Lynch P.G., Keogh A.J.
Annals of Saudi Medicine. Vol 14, No 6. 1994. 507-510.
37. **Surgical and non-surgical treatment of symptomatic intracranial meningiomas.**
Davis C.
British Journal of Neurosurgery. 1995; 9(3): 296-302.
38. **Spinal cord compression caused by ossification of the transverse ligament of the atlas.**
Perera S., Davis C., Gupta R.C.
British Journal of Neurosurgery. 1995; 9(6): 787-788.
39. **Preliminary studies on the pharmacokinetics of megadose tamoxifen in CNS tumour patients.**
Shaw I.C., Hudson S. A., Bruce S., Collinson T. D., Davis C.
British Journal of Neurosurgery. 1995; 9: Page 253 – 254.
40. **Decompression of spinal metastasis.**
Davis C.
Journal of Neurosurgery. 1996; 84(1): 150.
41. **Study of mega dose Tamoxifen and recurrent malignant glioma.**
Davis C., Shaw I.
British Journal of Neurosurgery 1996;10: 115-116.
42. **Tamoxifen enters meningiomas following oral mega-doses.**
Shaw C., Wood B., Davis C.
British Journal of Neurosurgery 1996;10: 125.
43. **Spinal meningeal melanocytoma: a case report and review of the literature.**
Sankhla S.K.Lynch P.G., Davis C.
British Journal of Neurosurgery. 1996: 10(2): 205-209.
44. **Shunt verses subarachnoid reconstruction.**
Davis C.
Journal of Neurosurgery. 1997; 87(4): 652.
45. **Malignant intracerebral tumours-long-term remission of recurrences treated with novel therapy.**
Butt A., Davis C.
British Journal of Neurosurgery. 1998;12: Page 185.
46. **Progesterone and oestrogen receptors in meningiomas: a series from the Royal Preston Hospital.**
O'Donovan D.G., Clayton A., Pitt M.A., Saeed K., Davis C., Lynch P.
British Journal of Neurosurgery 1998;12: Page 186.

47. **Intramedullary pressure in syringomyelia: clinical and pathophysiological correlates of syrinx distension.**
Davis C.
Neurosurgery. 1998; 42(6):1403.
48. **Will new cancer guidelines reduce delay in the diagnosis of brain tumours?**
I.D. Kamaly Asl, S. Clements, N. Joseph, C.H.G. Davis.
British Journal of Neurosurgery 15,6. 2001. Page 541.
49. **Some further thoughts on the aetio-pathology of syringomyelic experience with surgical management.**
Pragnesh Bhatt, Venkatachalam Iyer, W. Gunawardena, Charles Davis.
Supplement to work Congress on Syringomyelia 2001.
50. **Theatre time utilisation.**
R.V. Iyer, A.M. Likhith, S. Perera, J. MacLean, C.H.G. Davis,
British Journal Neurosurgery 16, 4. 2002. Page 408.
51. **Chemosensitivity testing in malignant gliomas;** Iyer, V., Roberts, P., Dawson, T., Davis, C., and Lea, R.W. IXth World Congress on Advances in Oncology, Crete. Abstract published in 'International Journal of Molecular Biology', Supplement, October 2004.
52. **Chemosensitivity testing in primary cultures form malignant gliomas.** Venkatachalam, I., Roberts, P., Lea, R.W. Ashton, K., Dawson, T., Golash, A., and Davis, C. (2005). Toxicology 213, p.229. 2005. (Abstract)
53. **Diagnosis and treatment of malignant glioma.** In: 'Molecular and Cellular Pathology of Cancer Progression and Prognosis'. Iyer, R.V., Golash, A., Lea, R.W., Davis, C. and Roberts P. (2006).. Research Signpost, 379-408.
54. **The colormetric MTS assay or the luminescent ATP assay: which is better for chemosensitivity testing in gliomas?** Iyer, R.V., Roberts, P., Lea, R.W., Dawson, T.P., Ashton, K., Golash, A., and Davis, C.H.G. Neuro-oncology. 2006 (Abstract)
55. **Selecting drug of choice in glioma chemotherapy: is in vitro testing the way forward?**
R.V.Iyer, P.Roberts, R. W. Lea, T. P. Dawson, A. Golash & C. H. G. Davis British Journal of Neurosurgery (Abstract) 2007. 49.
56. **Meningiomas causing focal neurological deficits: results of a surveillance strategy.**
A. Ray, H.C. Patel, G. Jackson, Q. Choudry & C. H .G. Davis. British Journal of Neurosurgery (Abstract) 2007.
57. **Gemcitabine in the treatment of gliomas.** Abeygunaratne R., Davis C., Golash, A., Roberts G., Lea R.W., Roberts P., Ashton K. and Dawson T. British Journal of Neurosurgery. 2008. (Abstract)
58. **Do MGMT inhibitors increase sensitivity of glial cultures to Temozolomide? Results from 25 glioma cultures.** Abeygunaratne R., Davis, C., Golash A., Roberts G., Lea R.W., Roberts P., Ashton K. and Dawson T. British Journal of Neurosurgery. 2008. (Abstract)
59. **Chemosensitivity testing in malignant glioma.** Abeygunaratne R., Dawson T.P., Davis C., Golash A., Roberts P. and Lea R.W. (2008). Journal of Medical Sciences. Supp 1, 12-17.

60. **“Long term survival” of glioma patients with “salvage” intra-arterial Cisplatin chemotherapy.** Lekka E., Davis C H. British Journal of Neurosurgery – Page 480 (Abstract) 2009.
61. **Glioblastoma: Can we predict a patient’s survival?** Parks C.J., Law J., Davis C.H., Hall G. British Journal of Neurosurgery – Page 481 (Abstract). 2009.
62. **The MTS versus the ATP assay for in vitro chemosensitivity testing of primary glioma tumour culture.**
Dawson T P, Iyer R V, Lea R W, Roberts P, Harris F, Ashton K, Golash A, and Davis CHG NeuroPath and Applied Neurobiology, 36; 564-7 (2010).
63. **Extraneural Metastasis of Medulloblastoma Via Surgical Track in Adult Patient**
Apok V, Ray A, Davis C.
(Abstract) Neuro-Oncology Supplement June 2010 Page 11.
64. **Survival of Patients with Glioblastoma.**
Bailey M, Lekka E, Law J, Davis C.
Abstract Neuro-Oncology June 2011.
65. **Cytokine measurement in pre and post-operative serum samples of high grade glioma patients using Luminex technology.**
Lekka E., Abel P, Dawson T, Lea R, Davis C.
Abstract Neuro-Oncology June 2011.
66. **Cell Survival Assays for Individualised Chemotherapy in Primary Glioma Cultures – Colourmetric or Luminescent?**
Dawson T P, Ashton K, Golash A, Davis C, Iyer R V, Lea R W, Roberts P, Harris F.
Neuroscience & Medicine 2011.
67. **Progesterone and Meningiomas.**
Davis C (Letter) Journal of Neurosurgery Page 560, 2011.
68. **Hartshill Frame Fixation for Posterior Spinal Stabilisation: A simple Technique in the Era of Pedicle Screw Rod Fixation.**
Razzaq A A, Hajra D, Iqbal M, Ray A, Golash A, Davis C.
Abstract British Journal of Neurosurgery September 2011.
69. **A large long-term radiological study of meningiomas, including first long-term report of anti-progesterone therapy with Gestrinone.**
Sainis, Paul G, Davis C.
Abstract to be published Neuro-Oncology 2012.H
- HH
H
70. **Gliadel Wafer Therapy, Our Experience.**
Lilot I, Iqbal M, Law J, Ray A, Davis C.
British Neuro-Oncology Society June 2012 (Neuro-Oncology Poster June 2012).

- 71. Meningioma – predicting recurrence. A large and longterm retrospective and prospective clinical and neuropathological study.**
C Davis, T Lilo, J Joseph, N Park, I Kamaly-Asal,
British Neuro-Oncology Society Meeting, Durham, 2013.
- 72. Predicting recurrence of meningioma. A large and long-term retrospective and clinical and neuropathological study.**
C Davis, Lilo T, Joseph J, Park N, Kamaly-Asal I.
Society of British Neurological Surgeons, Essex 2013 (Abstract British Journal of Neurosurgery)
- 73. Investigating the use of Immersion Raman Spectroscopy as a Histopathological Tool to Identify Metastatic Brain Tumours and Their Sites of Origin.**
Leanne M Fullwood, Franck Bonnier, Timothy P Dawson, Katherine Ashton, Charles Davis, David Griffiths, Robert W Lea, Hugh, J Byrne and Matthew J Baker.
British Neuro-Oncology Society Meeting, Durham, 2013 (Abstract Neuro-Oncology)
- 74. Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) Spectral Discrimination of Brain Tumour Severity from Serum Samples.**
James R Hands, Konrad M Dorling, Peter Abel, Katherine M Ashton, Andrew Brodbelt, Charles Davis, Timothy Dawson, Michael D Jenkinson, Robert W Lea, Carol Walker and Matthew J Baker.
British Neuro-Oncology Society Meeting, Durham, 2013 (Abstract Neuro-Oncology)
- 75. Investigating the use of Immersion Raman spectroscopy for the diagnosis of metastatic brain tumours and their primary cancer sites.**
Leanne M Fullwood, David Griffiths, Robert W Lea, Charles Davis, Katherine Ashton, Timothy Dawson, Franck Bonnier, Hugh Byrne and Matthew J Baker.
British Neuro-Oncology Society Meeting, Durham, 2013 (Abstract Neuro-Oncology)
- 76. Multi-gene methylation analysis to identify signature genes from brain metastasis from primary breast tumours.**
Rajendra P Pageni, Kate Ashton, Carol Walker, Tim Dawson, Charles Davis, Farida Latif, John L Darling, Tracy J Warr, Mark R Morris.
British Neuro-Oncology Society Meeting, Durham, 2013 (Abstract Neuro-Oncology)
- 77. Retrospective Evaluation of the Graded Prognostic Assessment (GPA) Score for Patients Treated with Stereotactic Radiotherapy (SRT).**
Singh N, Mehmood Q, Payne A, Ray A, Davis C.
NCRI Liverpool 2013 (Abstracts)
- 78. The rapid diagnosis of gliomas via serum spectroscopy.**
Hands J.R. Dorling, K.M, Lea R.W, Ashton K, Dawson T, Davis C, Brodbelt A, Jenkinson M, Walker C, Baker M J.
Published Neuropathology and Applied Neurobiology (proceedings British Neuropathological Society Meeting 2014). 40. (Suppl.1)
- 79. Identification of genes epigenetically deregulated in brain metastasis from primary breast tumours.**
Pageni R, Ashton K, Walker C, Dawson T, Davis C, Latif F, Darling J, Warr T, Morris M.
British Neuro-Oncology Society Meeting, Liverpool, 2014 (Oral Poster)
Abstract Published Neuro-Oncology Peer Review Supplement 2014.

- 80. Serum Spectroscopy of Brain Tumours: a rapid and accurate diagnostic tool.**
J.R.Hands, K.M. Ashton, A Brodbelt, C Davis, T Dawson, M.D. Jenkinson, R.W. Lea, C Walker, G. Clemens, M J Baker.
British Neuro-Oncology Society Meeting, Liverpool 2014 (Oral Poster)
Abstract Published Neuro-Oncology Peer Review Supplement 2014.
- 81. The Sound of Science: Developing the Spectral Light Orchestra.**
Ashton K, Brodbelt A., Davis C., Dawson T., Lea R.W., Walker C, Stables R, Vicinanza D, Jenkinson M.D., Clemens G, Baker M.J.
British Neuro-Oncology Society Meeting, Liverpool 2014 (Oral Poster)
Abstract Published Neuro-Oncology Peer Review Supplement 2014.
- 82. Identification of Glioma Specific Aptamer Targets.**
Arora M, Alder J, Lawrence C, Davis C, Dawson T, Hall G, Shaw L.
British Neuro-Oncology Society Meeting, Liverpool 2014 (Poster)
Abstract published Neuro-Oncology Peer Review Supplement 2014.
- 83. Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) spectral discrimination of brain tumour severity from serum samples.**
Hands J, Dorling K, Abel P, Ashton K, Brodbelt A, Davis C, Dawson T, Jenkinson M, Lea R, Walker C, Baker M.
Journal of Biophotonics 1-11, 2014.
- 84. Developing Stratified Serum Spectroscopic Diagnostics for Brain Tumours: Finding the Features.**
Hands J, Clemens G, Lea R, Ashton K, Dawson T, Jenkinson M, Brodbelt A, Davis C, Stables R, Baker M.
Abstract publication Neuro-Oncology 2015.
- 85. Distribution of Mg, Fe, Cu and Zn in glioblastoma, meningioma I and II using inductively coupled plasma mass spectrometry (ICP-MS)**
Mudariki T, Lea R, Ashton K, Dawson T, Davis C, Smith J.
Abstract publication Neuro-Oncology 2015.
- 86. The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain.**
Pangeni R, Channathodiyil P, Huen D, Eagles L, Johal B, Pasha D, Hadjistephanou N, Nevell O, Davies C, Adewaumi A, Khanom H, Samra I, Buzatto V, Chandrasekaran P, Shinawi T, Dawson T, Ashton K, Davis C, Brodbelt A, Jenkinson M, Bièche I, Latif F, Darling J, Warr T, Morris M.
Clinical Epigenetics Journal 4.54 Pages 1 – 25 June 2015.
- 87. The Cumbria Spinal Service – Five years audit of micro-discectomy and micro-decompression.**
Smith R, Davis C, Gardner C.
European Spine Journal BASS Supplement 2015.
- 88. UCL and Tim Hunt.**
Davis C, Times letter section 25.02.2015.
- 89. Brain tumour differentiation: rapid stratified serum diagnostics via attenuated total reflection Fourier-transform infrared spectroscopy.**
Hands JR, Clemens G, Stables R, Ashton K, Brodbelt A, Davis C, Dawson TP, Jenkinson MD, Lea RW, Walker C, Baker MJ. J Neurooncol. 2016 May;127(3):463-72.
- 90. Identifying epigenetic changes in breast tumours that metastasise to the brain.**
Olivares I, Davis C.
NCRI 2017

91. **APGG Brain Tumours – House of Commons June 2018. Social and economic effects of Brain tumours.**
Davis C – on behalf of Brain Tumour North West.
92. **A pilot study of the acceptance of tolerability of tumour treating fields in adult glioblastoma patients.**
Broadbelt A, Williams M, Thorpe A, Mills S, Price S, Lekka E, Watts C, Davis C, Jenkinson M.
British Neuro-Oncology Society Annual Meeting 2018.
(To be published)
93. **Inhibiting Hexokinase 2 implicates a reduction of cell proliferation and drug resistance.**
Blakeway D, Karakoula K, Morris M, Eagles L, Rowther F, Ashton K, Davis C, Dawson t, Darling J, Warr T.
British Neuro-Oncology Society Annual Meeting 2018.
(To be published)
94. **Effects of dietary lipids on cell viability and stemness in glioblastoma spheroids.**
Nicholls S, Davis C, Alder J.
British Neuro-Oncology Society Annual Meeting 2018.
(To be published).

PRESENTATIONS TO LEARNED SOCIETIES

1. **Cerebellar astrocytomas in children and young adults.**
Davis C., Jolekar V.
Society of British Neurological Surgeons. 1980.
2. **Management of cerebral angiomas. Review of 129 cases.**
Davis C., Symon L.
Society of British Neurological Surgeons. 1983.
3. **History of Maida Vale Hospital.**
Davis C., Bradford R.
Poster display. Second International Symposium on Brain Tumours. 1984
4. **Oestrogen receptors and brain tumours.**
Davis C., Thomas D.
Surgical Research Society. 1985
5. **Steroid sex hormones and meningiomas.**
Davis C., Jones J., Yoshino E., Darling J., Carter G., Zaher J., Thomas D.
Society of British Neurological Surgeons. 1986
6. **Steroid sex hormones and non-pituitary brain tumours.**
Davis C., Darling J., Yoshino E., Jones J., Carter G., Zaher J., Thomas D.
European Neuro-oncology. Rennes. 1986.

7. **Case of brainstem haematoma treatment with CT stereotaxic aspiration.**
Davis C., Thomas D.
Royal Society of Medicine. 1986.
8. **Mechanisms in syringomyelia.**
Davis C.
Surgical Research Society. 1987
9. **N.M.R. spectroscopy in cerebral gliomas.**
Ross B., Davis C., Thomas D.
Surgical Research Society. 1987.
10. **C.T. Stereotactic surgery of brainstem lesions.**
Bradford R., Davis C., Thomas D.G.
Society of British Neurological Surgeons. 1987
11. **N.M.R. spectroscopy in cerebral tumours.**
Ross B., Davis C., Thomas D.
International Neuro-oncology. Royal Marsden Hospital. 1988.
12. **An empty sphenoid mucocele.**
Davis C., Small., Lund V.
North of England Neurological Association. 1988.
13. **A modified Leksell stereotactic apparatus.**
Sofat A., Jones A., Davis C., Gurusinghe N.
Society of British Neurological Surgeons. 1989.
14. **Sex hormones and meningiomas.**
Davis C.
Surgical Research Society. 1989.
15. **Absent cervical pedicle.**
Bhatt P., Davis C.
British Cervical Spine Society. 1989.
16. **Experience with the CRW stereotactic frame.**
Pandya P., Davis C.
British Neuro-oncology Group. 1990.
17. **Complications of anterior cervical surgery.**
Davis C.
British Cervical Spine Society. 1990.
18. **Designer surgery for the 90's.**
Parekh P., Davis C.
Surgical Research Society. 1991.
19. **Intracarotid Cisplatin chemotherapy for malignant glioma –Is it worth it?**
Pandya P., Davis C.
Second International Neuro-oncology. Royal Marsden Hospital. 1991.

- 20. Meningiomas and sex hormones.**
Davis C.
Society of British Neurological Surgeons. 1991.
- 21. Visual disturbances following anterior cervical surgery. Another disaster.**
Davis C.
British Cervical Spine Society. 1991.
- 22. Stereotactic surgery for the 90's with the CRW frame.**
Sharma R. Parekh H., Davis C.
British Neuro-oncology Group. 1992.
- 23. Extralateral lumbar disc.**
Davis C.
Symposium on Diseases of the Spinal Cord (invited). 1992.
- 24. Anterior cervical discectomy the Neurosurgical point of view.**
Parekh H., Davis C.
British Cervical Spine Society. 1992.
- 25. Delayed diagnosis of odontoid fractures.**
Prabhu S., Davis C.
British Cervical Spine Society. 1992.
- 26. Medicolegal case of whiplash.**
Snipe I., Davis C.
British Cervical Spine Society. 1992.
- 27. Medical Treatment of subarachnoid haemorrhage.**
Davis C.
Surgical Research Society. 1993.
- 28. Treatment of malignant glioma with short course radiotherapy and PCV regime.**
Prabhu S., Davis C.
British Neuro-oncology Group. 1993.
- 29. Cervico-medullary compression caused by calcified ligamentum transversarium.**
Perera S., Davis C.
British Cervical Spine Society. 1993.
- 30. Spinal tumour and whiplash.**
Davis C.
British Cervical Spine Society. 1993.
- 31. Short-term radiotherapy of malignant glioma**
Davis C.
British Neuro-oncology Group. 1993.
- 32. Compression of cervical cord by calcified ligamentum transversarium.**
Sharma R., Davis C.
British Cervical Spine Society. 1993.

33. **Preliminary studies in the Pharmacokinetics of mega dose Tamoxifen in CNS tumours.**
Bruce S., Hudson S., Collinson T., Shaw I., Davis C.
British Neuro-oncology Group. 1994.
34. **Surgical and non-surgical treatment of cranial meningiomas.**
Davis C.
British Neuro-oncology Group. 1994.
35. **Study of mega dose Tamoxifen and recurrent malignant glioma.**
Davis C., Shaw I.
British Neuro-oncology Group. 1995.
36. **Tamoxifen enters meningiomas following oral mega doses.**
Shaw I., Wood B., Davis C.
British Neuro-oncology Group. 1995.
37. **Quality of life in malignant glioma.**
Lyons S., Davis C.
European Association Neurosurgical Societies. 1995
38. **Chemotherapy for malignant glioma**
Davis C.
Society of British Neurological Surgeons. 1996.
39. **Meningiomas and sex hormonal receptors.**
O'Donovan D., Davis C., Lynch P.
British Neuro-Oncology Group. 1997
40. **Cervical Spine Fractures.**
Smith R., Davis C.
British Cervical Spine Society. 1998.
41. **Meningiomas and sex hormones revisited.**
O'Donovan D., Davis., Lynch P.
British Neurosurgery Research Society. 1998.
42. **Malignant intracerebral tumours- long-term remission of recurrences treated with novel therapy.**
Butt A., Davis C.
British Neuro-Oncology Group 1998.
43. **Progesterone and oestrogen receptors in meningiomas: a series from the Royal Preston Hospital.**
O'Donovan D.G., Clayton A., Pitt M.A., Saeed K., Davis C., Lynch P.
British Neuro-Oncology Group 1998.
44. **Review of the Aetiopathogenesis of Syringomyelia**
Poster presentation at the 'Cervical Spine Research Society Annual Meeting' May 2000 London.
Iyer RV, Davis CHG.

- 45. Triumphs and Disasters in Rheumatoid Surgery.**
Poster presentation at the 'Cervical Spine Research Society Annual Meeting' May 2000 London.
Davis C., Smith R.
- 46. Cavalier King Charles Spaniel and Syringomyelia.**
Platform presentation 'Cervical Spine Research Society Annual Meeting' May 2000 London.
Skerritt G., Davis C.
- 47. Revisiting the Pathogenesis of Syringomyelia**
Platform presentation and abstract publication at the 'World Conference on Syringomyelia',
Tokyo Japan, June 2000.
Bhatt P, Iyer RV, Davis CHG.
- 48. Referral Patterns of Malignant Gliomas and Outcome**
Platform presentation and abstract publication at the 'SBNS Spring Meeting' 2001.
Kamaly – Asl I, Habib, Davis CHG.
- 49. CRW Frame in Brain Tumours**
Platform presentation and abstract publication '5th Indian conference of 'Functional and
Stereotactic Neurosurgery', Oct 2001.
Likhith AM, Iyer RV, Davis CHG.
- 50. Theatre Time Audit in Neurosurgery**
Poster presentation and abstract publication 'SBNS September Meeting' London.
Iyer RV, Davis CHG, Likhith AM, Perera S.
- 51. Referral Patterns of Malignant Gliomas and Outcome**
Platform presentation and abstract publication at the 'British Neuro-Oncology Group Meeting'
June 2001.
Habib, Kamaly – Asl I, Davis CHG.
- 52. The Mystery of Syringomyelia**
Platform presentation at the 'North of England Neurological Association Meeting'. November
2001, Harrogate.
Iyer RV, Davis CHG.
- 53. Missed Cervical Spine Injuries**
Platform presentation at the 'British Cervical Spine Society Meeting'. November 2001. Stratford
upon Avon.
Rao MR, Iyer RV, Davis CHG.
- 54. Improvement in Patient documentation using the Handheld Computerised Database of Referrals**
Poster presentation and abstract publication. 'SBNS Autumn Meeting' 2002.
Kamaly – Asl, Davis CHG.
- 55. Chiari I Malformation in Identical Twins**
Presentation at the 'President's Prize Evening at the Royal Society of Medicine London' Feb
2002.
Iyer RV, Davis CHG.

- 56. Progesterone Receptors in Meningiomas**
Platform presentation and abstract publication 'SBNS Autumn Meeting' 2002.
Kamaly Asl, Davis CHG.
- 57. Stereotactic Biopsy of Brain Tumours**
Platform presentation at the 'British Neuro-Oncology Group Annual Meeting' June 2002.
Likhith AM, Iyer RV, Davis CHG.
- 58. Identification of Progesterone Receptors in Astrocytomas and Oestrogen Induction**
Platform presentation at the 'British Neuro-Oncology Group Meeting' June 2002.
Rao MR, Lee, Golash A., Davis CHG.
- 59. Framed Stereotaxy in Malignant Glioma – The Preston Experience**
Presentation at the 'British Stereotactic and Functional Group Meeting' August 2002.
Iyer RV, Likhith A, Davis CHG.
- 60. The President's Nightmare.**
Davis CHG.
Presentation to the President of the Royal College of Surgeons, Preston 2002.
- 61. Prognostic factors relating to female sex steroids and receptors in meningiomas.**
Kamaly Asl I, Clayton A, Dawson T, O'Donovan D, Davis C.
Society of British Neurological Surgeons. Presentation 2002.
- 62. Sex Hormones and Brain Tumours**
Davis CHG
National Hospital for Neurology and Neurosurgery Twenty Five Years Research Meeting.
- 63. Loves Labours Lost – Can the NHS Deliver Care for Primary Malignant Glioma?**
Davis CHG, Likhith A, Clements S, Habib M, Kamaly Asl I.
British Neuro-Oncology Group Meeting June 2003.
- 64. Effect of Tamoxifen on Fatty Acid Metabolism in Astroglial Tumour Cell Lines.**
Rao R, Lea R, Golash A, Davis CHG.
British Neuro-Oncology Group Meeting June 2003.
- 65. Cerebral Vasospasm Norsah Study.**
Iyer V, Hunt L, Lye R, Davis CHG.
International Conference on Vasospasm Chicago July 2003.
- 66. 17-b Estradiol Increases Highly Unsaturated Fatty Acids (HUFA) in Astroglial tumour.**
Rao M., Lea R., Golash A., Davis C.
British Neuro-Surgery Research Group 2003.
- 67. Effects of Oestrogen and Tamoxifen on glioma cell lines.** Rao, R., Golash, A., Davis C., and Lea R.W. British Neuro-Oncology Society Meeting, Cambridge.
- 68. Effects of Tamoxifen on P24/44 Map Kinase in Human Glioma Cell Line.** Rao R.M., Golash A. Davis C. and Lea R.W., Society of British Neurological Surgeon, 2003.

69. **In Vitro Culture of Glioma Cell Lines: Effects of Tamoxifen and Estrogen.** Rao, R.M., Golash A., Davis C. and Lea R.W. Annual Research Conference, Lancashire Teaching Hospital NHS Trust, Preston.
70. **Factors Influencing Vasospasm in Aneurysmal Subarachnoid Haemorrhage in the North of England. A prospective observational study.** Iyer R., Hunt L, Roberts G., Gurusinghe N., Davis C., Lye R. Society of British Neurological Surgeons 2004
71. **Chemosensitivity Testing Gliomas.** Iyer R., Roberts P, Lea R., Ashton K., Dawson T., Golash G, Davis C. 9th World Congress of Progress in Oncology 2004.
72. **The Effects of Tamoxifen on Glioma Line Cells.** Roberts P., Rao M.R., Golash A., Davis C., Mikita J. and Lea R.W. (2004). Invited Lecture, Predictive Oncology Meeting, Portsmouth.
73. **Long-term follow up in patients with meningiomas causing focal neurological deficits. Results of a surveillance strategy.** Choudry Q., Patel HC., Jackson G., Davis CH. European Association of Neurosurgical Societies (Prague) 2005.
74. **Comparison of assays in Chemosensitivity testing of Gliomas;** Iyer R.V., Roberts P., Lea R.W., Dawson T.P., Ashton K., Golash A., Davis C.H.G. (2005). European Association of Neurological Surgeons (EANS) winter meeting, Prague, February 2005.
75. **Chemosensitivity testing in Gliomas** Iyer R.V., Roberts P., Lea R.W., Dawson T.P., Ashton K., Golash A., Davis C.H.G. (2005).; British Neurosurgical Research Group, London, March 2005.
76. **Practical methodology of primary cell culture and chemosensitivity testing in gliomas** Iyer R.V., Roberts P., Lea R.W., Dawson T.P., Ashton K., Golash A., Davis C.H.G. (2005).; National Cellular pathology discussion group symposium, Preston, March 2005.
77. **The way forward – Glioma culture and chemosensitivity testing.** Iyer R.V., Roberts P., Lea R.W., Dawson T.P., Ashton K., Golash A., Davis C.H.G. (2005). Neuro-Oncology symposium, Division of Radiobiology, VU University, March 2005, Amsterdam.
78. **Comparing the Colormetric and luminescent assays in chemosensitivity testing of Gliomas;** Iyer R., V., Roberts P., Lea R.W., Dawson T.P., Ashton K., Golash A., Davis C.H.G. (2005). British Toxicology Society Annual Conference, Warwick, March 2005.
79. **Chemosensitivity testing in Gliomas: Preliminary results.** Iyer R.V., Roberts P., Lea R.W., Dawson T.P., Ashton K., Golash A., Davis C.H.G. (2005). Society of British Neurological Surgeons, Spring meeting, Edinburgh, April 2005.

80. **The Colorimetric MTS assay or the Luminescent ATP assay: which is better for chemosensitivity testing in Gliomas** Iyer R.V., Roberts P., Lea R.W., Dawson T.P., Ashton K., Golash A., Davis C.H.G. (2005). 11th International Congress of the World Federation of Neuro-Oncology, May 2005, Edinburgh.
81. **Chemosensitivity testing in malignant gliomas: from Lab to the bedside?** Iyer R.V., Roberts P., Lea R.W., Dawson T.P., Ashton K., Golash A., Davis C.H.G. (2005). World Federation of Neurological Surgeons, Annual Conference, June 2005, Marrakesh.
82. **Is targeting drug treatment the way forward in glioma chemotherapy?** Iyer,R.V., Roberts P., Lea R.W., Dawson T.P., Golash A. and Davis C.H.G. (2006) Annual Meeting of the British Neuro-Oncology Society, (BNOS), Institute of Neurology, London, 21st – 23rd June 2006.
83. **Selecting Drug of Choice in Glioma Chemotherapy: Is In Vitro Testing the Way Forward?** Davis C., Iyer R., Roberts P., Lea R., Dawson T., Golash A. Society of British Neurological Surgeons 2006.
84. **Meningiomas Causing Focal Neurological Deficit: Results of a Surveillance Strategy.** Ray A., Patel H., Jackson G., Choudry Q., Davis C. Society of British Neurological Surgeons 2006.
85. **Age and Sex Distribution of Primary Malignant Gliomas – An Eight Year Single Centre Study.** Abeygunaratne R., Iyer V., Ray A., Ahmad A., Davis C. Society of British Neurological Surgeons 2006 (Poster).
86. **Development of chemosensitivity testing in vitro for glioma.** Dawson T., Iyer V., Davis C., Roberts P., Lea R.W. (2007). BNOS Annual Meeting, Portsmouth, 2007.
87. **Chemosensitivity testing in malignant glioma.** Lea R.W., Dawson T., Iyer V., Golash A., Davis C. and Roberts P. (2007). 1st Emirates Hellenic Medical Conference, Dubai. 2007.
88. **Do systemic diseases affect outcome of surgery in cervical myelopathy?** Ramaswamy R., Ughratdar I., Panikar S., & Davis C H. (Royal Preston Hospital, Preston, UK) Society of British Neurological Surgeons February 2007; (Poster).
89. **Age and sex distribution of primary malignant gliomas – a 8 year single centre study.** Abeygunaratne R. S., Iyer V., Ray A., Ahmad A. & Davis C.(Royal Preston Hospital) Society of British Neurological Surgeons February 2007;
90. **Old drugs, new tricks.** Abeygunaratne R., Davis C., Golash A., Roberts G., Lea R., Roberts P., K Ashton., Dawson T. Annual Meeting of the British Neuro-Oncology Society (BNOS), University of Portsmouth 2007.
91. **Development of chemosensitivity testing in vitro for glioma.** Dawson T., Iyer V., Davis C., Roberts P., Lea R.W.. BNOS Annual Meeting, Portsmouth 2007.

92. **Chemosensitivity testing in malignant glioma.** Lea R.W., Dawson T., Iyer V., Golash A., Davis C. and Roberts, P. 1st Emirates Hellenic Medical Conference, Dubai, United Arab Emirates, 6th – 8th December (Invited plenary lecture).
93. **Individualising chemotherapeutic treatment for glioma patients.** Abeygunaratne, R., Davis, C., Lea, R.W. and Dawson, T. NHS Regional Cancer Meeting, Liverpool, October 2007.
94. **Testing novel drug combinations for glioma treatment – old drugs, new tricks.** Abeygunaratne R., Davis C., Lea R.W. and Dawson T. Annual British Neuropathology Society, London. 2008.
95. **Old drugs, new tricks. Gemcitabine sensitive gliomas.** Abeygunaratne R., Davis, C., Lea, R.W. and Dawson T. International Neuropathology Meeting. Athens. 2008.
96. **Bespoke chemotherapeutic treatment for glioma patients.** Abeygunaratne, A., Davis C., Golash A., Lea R.W. and Dawson T. Regional Research Meeting, RPH. 2008.
97. **Development of in vitro chemosensitivity testing for neuro-oncology.** Lea R.W., Darling J., Davis C. and Dawson, T. 22nd Annual Neurosurgical Congress, Athens, 11th – 14th June 2008.
98. **Gemcitabine in the treatment of gliomas.** Abeygunaratne R., Davis C., Golash A., Roberts G., Lea R.W., Roberts P., Ashton K. and Dawson, T. (2008) . British Neuro-Oncology Society Annual Meeting, Preston. 2008.
99. **Do MGMT inhibitors increase sensitivity of glial cultures to Temozolomide? Results of 25 glioma cultures.** Abeygunaratne R., Davis C., Golash A., Roberts G., Lea R.W., Roberts P., Ashton K. and Dawson T., British Neuro-Oncology Society Annual Meeting, UCLAN, Preston. 2008.
100. **“Long term survival” of glioma patients with “salvage” intra-arterial Cisplatin chemotherapy.** Lekka E., Davis C H., Society of British Neurological Surgeons 2009.
101. **Glioblastoma: Can we predict a patient’s survival?** Parks C.J., Law J., Davis C.H., Hall G. Society of British Neurological Surgeons 2009.
102. **Extraneural Metastasis of Medulloblastoma Via Surgical Track in Adult Patient**
Apok V, Ray A, Davis C.
(Abstract) British Neuro-Oncology Society June 2010.
103. **Cytokine measurement in pre and post-operative serum samples of high grade glioma patients using Luminex technology.**
Lekka E., Abel P, Dawson T, Lea R, Davis C.
British Neuro-Oncology Society June 2011.

104. **A large long-term radiological study of meningiomas, including first long-term report of anti-progesterone therapy with Gestrinone.**
Sainis, Paul G, Davis C.
(Abstract) British Neuro-Oncologist Society Poster June 2012. H
- HH
H
105. **Gliadel Wafer Therapy, Our Experience.**
Lilot I, Iqbal M, Law J, Ray A, Davis C.
British Neuro-Oncology Society June 2012.
106. **Increasing Incidence of Metastatic Brain Tumours; an epidemic in waiting.**
(Poster) British Neuro-Oncology Society 2012
Ora M, Davis C.
107. **The Walton Centre and Brain Tumour North West Research Tissue Banks: Progress Report**
C Walker, A Brodbelt, M Jenkinson, D Crooks, K Ashton, A Ray, M Arora, C Davis and T Dawson.
British Neuro-Oncology Society Meeting, Durham, 2013.
108. **Meningioma – predicting recurrence. A large and longterm retrospective and prospective clinical and neuropathological study.**
C Davis, T Lilo, J Joseph, N Park, I Kamaly-Asal,
British Neuro-Oncology Society Meeting, Durham, 2013.
109. **Comparison of a graded prognostic assessment with Recursive Partitioning analysis as a prognostic tool for patients undergoing Stereotactic Radiotherapy for brain metastases.**
Singh N, Mehmood Q, Payne A, Ray A, Davis C.
Society British Neurological Surgeons 2013
110. **The history of Maida Vale Hospital, Neurophysiology and Serendipity.**
Davis C.
Annual Meeting of the British Society of Clinical Neurophysiologists.
111. **Predicting recurrence of meningioma. A large and long-term retrospective and clinical and neuropathological study.**
C Davis, Lilo T, Joseph J, Park N, Kamaly-Asal I.
Society of British Neurological Surgeons, Essex 2013 (Abstract British Journal of Neurosurgery)
112. **Investigating the use of Immersion Raman Spectroscopy as a Histopathological Tool to Identify Metastatic Brain Tumours and Their Sites of Origin.**
Leanne M Fullwood, Franck Bonnier, Timothy P Dawson, Katherine Ashton, Charles Davis, David Griffiths, Robert W Lea, Hugh, J Byrne and Matthew J Baker.
British Neuro-Oncology Society Meeting, Durham, 2013 (Abstract Neuro-Oncology)
113. **Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) Spectral Discrimination of Brain Tumour Severity from Serum Samples.**
James R Hands, Konrad M Dorling, Peter Abel, Katherine M Ashton, Andrew Brodbelt, Charles Davis, Timothy Dawson, Michael D Jenkinson, Robert W Lea, Carol Walker and Matthew J Baker.
British Neuro-Oncology Society Meeting, Durham, 2013 (Abstract Neuro-Oncology)
114. **Investigating the use of Immersion Raman spectroscopy for the diagnosis of metastatic brain tumours and their primary cancer sites.**
Leanne M Fullwood, David Griffiths, Robert W Lea, Charles Davis, Katherine Ashton, Timothy Dawson, Franck Bonnier, Hugh Byrne and Matthew J Baker.
British Neuro-Oncology Society Meeting, Durham, 2013 (Abstract Neuro-Oncology)

- 115. Multi-gene methylation analysis to identify signature genes from brain metastasis from primary breast tumours.**
Rajendra P Pageni, Kate Ashton, Carol Walker, Tim Dawson, Charles Davis, Farida Latif, John L Darling, Tracy J Warr, Mark R Morris.
British Neuro-Oncology Society Meeting, Durham, 2013 (Abstract Neuro-Oncology)
- 116. Identification of genes epigenetically deregulated in brain metastasis from primary breast tumours.**
Pageni R, Ashton K, Walker C, Dawson T, Davis C, Latif F, Darling J, Warr T, Morris M.
British Neuro-Oncology Society Meeting, Liverpool, 2014 (Oral Poster)
- 117. Serum Spectroscopy of Brain Tumours: a rapid and accurate diagnostic tool.**
J.R.Hands, K.M. Ashton, A Brodbelt, C Davis, T Dawson, M.D. Jenkinson, R.W. Lea, C Walker, G. Clemens, M J Baker.
British Neuro-Oncology Society Meeting, Liverpool 2014 (Oral Poster)
- 118. The Sound of Science: Developing the Spectral Light Orchestra.**
Ashton K, Brodbelt A., Davis C., Dawson T., Lea R.W., Walker C, Stables R, Vicinanza D, Jenkinson M.D., Clemens G, Baker M.J.
British Neuro-Oncology Society Meeting, Liverpool 2014 (Oral Poster)
- 119. Identification of Glioma Specific Aptamer Targets.**
Arora M, Alder J, Lawrence C, Davis C, Dawson T, Hall G, Shaw L.
British Neuro-Oncology Society Meeting, Liverpool 2014 (Poster)
- 120. The rapid diagnosis of gliomas via serum spectroscopy.**
Hands J.R. Dorling K.M, Lea R.W, Ashton K, Dawson T, Davis C, Brodbelt A, Jenkinson M, Walker C, Baker M J.
British Neuropathological Society Meeting 2014 (Oral).
- 121. Distribution of Mg, Fe, Cu and Zn in glioblastoma, meningioma I and II using inductively coupled plasma mass spectrometry (ICP-MS)**
Mudariki T, Lea R, Ashton K, Dawson T, Davis C, Smith J.
British Neuro-Oncology Meeting 2015.
- 122. Developing Stratified Serum Spectroscopic Diagnostics for Brain Tumours: Finding the Features.**
Hands J, Clemens G, Lea R, Ashton K, Dawson T, Jenkinson M, Brodbelt A, Davis C, Stables R, Baker M.
British Neuro-Oncology Meeting 2015.
- 123. The Cumbria Spinal Service – Five years audit of micro-discectomy and micro-decompression.**
Smith R, Davis C, Gardner C.
British Association of Spinal Surgeons – 2015.
- 124. Meningiomas – where are we going?**
Davis C. Sanger Institute 2016.

- 125. A pilot study of the acceptance of tolerability of tumour treating fields in adult glioblastoma patients.**
Broadbelt A, Williams M, Thorpe A, Mills S, Price S, Lekka E, Watts C, Davis C, Jenkinson M.
British Neuro-Oncology Society Annual Meeting 2018.
- 126. Inhibiting Hexokinase 2 implicates a reduction of cell proliferation and drug resistance.**
Blakeway D, Karakoula K, Morris M, Eagles L, Rowther F, Ashton K, Davis C, Dawson t, Darling J, Warr T.
British Neuro-Oncology Society Annual Meeting 2018.
- 127. Effects of dietary lipids on cell viability and stemness in glioblastoma spheroids.**
Nicholls S, Davis C, Alder J.
British Neuro-Oncology Society Annual Meeting 2018.
- 128. Tumour Treating Fields Acceptable to UK Population**
Broadbelt A, Jenkinson M, Lekka E, Davis C
Society of Neuro-Oncology November 2018 New Orleans.
- 129. "Quality of life and tolerability of tumour treating fields in newly diagnosed glioblastoma in poorer prognosis patients. A pilot study".**
Agenor A, Thorpe A, Williams M, Jenkinson M, Davis C, Watts C, Brodbelt A.
Society of British Neurological Surgeons, Manchester 2019.